PMA device
Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation Psa
Siemens Healthcare Diagnostics, Inc. · Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF, Class III) · First FDA decision Dec 30, 2008, newest Jan 21, 2010Prostate cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Immulite Immulite 1000"
MAUDE reports
32
Brand "Immulite Immulite 1000", since 2015
PubMed studies
0
Mentioning "Immulite Immulite 1000"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Immulite/Immulite 1000/IMMULITE 2000/IMMULITE 2500 Psa & 3RD Generation Psa
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
P930027-S010 · Decided Jan 21, 2010 · 80 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
P930027-S007 · Decided Dec 30, 2008 · 50 days after receipt · Normal 180 Day Track No User Fee
Device type: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Prostate Specific AntigenNational determinationOn the books190.31Updated Oct 1, 2026
- Prostate Specific Antigen (Inclusion of ICD-9-CM Code 600.01 for BPH with Urine Obstruction)Coding analysisReview closedCAG-00232NUpdated Sep 15, 2026
- Prostate Specific Antigen (Addition of ICD-9-CM 600.00, Hypertrophy (benign) of Prostate Without Urinary Obstruction, as a covered indication)Coding analysisReview closedCAG-00326NUpdated Sep 15, 2026
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Immulite Immulite 1000", any status and sponsor, newest update first.
No registered device study names "Immulite Immulite 1000".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Immulite Immulite 1000", and for the whole product code for context.
This brand
32 reports: 32 malfunction, 0 injury, 0 death
Whole product code MTF
390 reports: 373 malfunction, 17 injury, 0 death
Newest reports for this brand
- IMMULITE/IMMULITE 1000 HCGMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
1219913-2024-00285 · Received Apr 10, 2024 · Event dated Mar 11, 2024
Device type: System, Test, Human Chorionic Gonadotropin (DHA)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- IMMULITE/IMMULITE 1000 HCGMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
1219913-2024-00286 · Received Apr 10, 2024 · Event dated Mar 21, 2024
Device type: System, Test, Human Chorionic Gonadotropin (DHA)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- IMMULITE/IMMULITE 1000 HCGMalfunction
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
1219913-2024-00287 · Received Apr 10, 2024 · Event dated Mar 28, 2024
Device type: System, Test, Human Chorionic Gonadotropin (DHA)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- IMMULITE 2000 PSA assay, Catalog Number L2KPTS2(D) (SMN 10706281) and Catalog Number L2KPTS6(D) (SMN 10706282)Open, Classified
Siemens Healthcare Diagnostics, Inc.
Z-0464-2025 · Started Sep 30, 2024 · Posted by FDA Nov 14, 2024
Reason given: The IMMULITE 2000 PSA assay for use on the IMMULITE 2000 and IMMULITE 2000 XPi analyzers did not meet the High-dose Hook Effect claim as stated in the Instructions for Use (IFU).
Cause as FDA categorized it: Under Investigation by firm · Device type: Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)
Siemens Healthcare Diagnostics, Inc.
Z-1119-2017 · Started Dec 21, 2016
Reason given: Negative bias with IMMULITE /IMMULITE 1000 Third Generation PSA (prostate-specific antigen) kit. The investigation by Siemens has confirmed that patient samples exhibit an average negative bias of approximately -22% with a range of -16% to -27% for samples recovering from 0.08 to 16.2 ng/mL.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)
Siemens Healthcare Diagnostics, Inc.
Z-1120-2017 · Started Dec 21, 2016
Reason given: Negative bias results with the IMMULITE /IMMULITE 1000 Third Generation PSA (prostate-specific antigen) kit was confirmed for two lots (D0119 and D0120). The investigation by Siemens has confirmed that patient samples exhibit an average negative bias of approximately -22% with a range of -16% to -27% for samples...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)
4 more recall records with a free account
Published research
The most relevant PubMed records for "Immulite Immulite 1000"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MTF.
- Elecsys total PSA, total PSA CalSet IIRoche Diagnostics Corp. · PMA 2023
- ARCHITECT Total PSA, Alinity i Total PSAAbbott Laboratories · PMA 2023
- Access Hybritech PSABeckman Coulter, Inc. · PMA 2024
- Dimension Vista Tpsa AssaySiemens Healthcare Diagnostics · PMA 2016
- Atellica IM Total PSA II (tPSAII)Siemens Healthcare Diagnostics, Inc. · PMA 2026
- Advia Centaur Psa AssaySiemens Healthcare Diagnostics · PMA 2017
- Axsym Total PsaAbbott Laboratories · PMA 2011
- Abbott Architect Total PsaAbbott Laboratories · PMA 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.